- Home
- ZLAB vs BCRX Comparison
ZLAB vs BCRX Comparison
Compare ZLAB & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | BCRX |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | BCRX |
|---|---|---|
| Price | $17.53 | $9.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $49.60 | $20.82 |
| AVG Volume (30 Days) | 680.7K | ★ 6.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | ★ $460,156,000.00 | $25,186,000.00 |
| Revenue This Year | $14.46 | N/A |
| Revenue Next Year | $29.47 | $12.55 |
| P/E Ratio | ★ N/A | $7.76 |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $6.00 |
| 52 Week High | $44.34 | $11.31 |
Technical Indicators
Market Signals| Indicator | ZLAB | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 65.87 |
| Support Level | $17.03 | $7.85 |
| Resistance Level | $19.49 | N/A |
| Average True Range (ATR) | 0.60 | 0.57 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 11.49 | 63.13 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.